ES2855700T3
Method for improving the stability of clopidogrel using sulfoalkyl ether cyclodextrin
Abstract
A composition comprising clopidogrel or a pharmaceutically acceptable salt thereof, an aqueous liquid carrier and a sulfoalkyl ether-cyclodextrin (SAE-CD); wherein the composition has a pH of 3.5 or higher, and wherein the molar ratio of SAE-CD to clopidogrel is at least 6: 1.
Term
1.6 yearsto projected expiry
Projected expiry 26 April 2028, counted from filing; an application has no term until it is granted.
- Priority
- Filed
- Published
- Today
- Projected expiry
12 sheets
Sheet 1 Sheet 2 Sheet 3 Sheet 4 Sheet 5 Sheet 6 Sheet 7 Sheet 8 Sheet 9 Sheet 10 Sheet 11 Sheet 12
61 members in 18 offices
Priority claims9
| Document | Office | Kind | Date |
|---|---|---|---|
| 914555P | United States of America | – | |
| 91455507 | United States of America | P | |
| 91455507 | United States of America | P | |
| 2008061697 | United States of America | W | |
| 2008061697 | United States of America | W | |
| 914555P | – | – | – |
| PCTUS2008061697 | – | – | – |
| US20070914555P | – | – | – |
| WO2008US61697 | – | – | – |
Members61
| Document | Office | Kind | |
|---|---|---|---|
| AU2008245550A1 | Australia | A1 | |
| CA2685331A1 | Canada | A1 | |
| CA2921601A1 | Canada | A1 | |
| WO2008134600A1 | World Intellectual Property Organization (WIPO) | A1 | |
| WO2008134601A1 | World Intellectual Property Organization (WIPO) | A1 | |
| MX2009011619A | Mexico | A | |
| KR20100017366A | Republic of Korea | A | |
| EP2152078A1 | European Patent Office (EPO) | A1 | |
| CN101686681A | China | A | |
| IL201776A0 | Israel | A0 | |
| IL201776D0 | Israel | D0 | |
| JP2010525083A | Japan | A | |
| US2010292268A1 | United States of America | A1 | |
| RU2009143991A | Russian Federation | A | |
| EP2152078A4 | European Patent Office (EPO) | A4 | |
| NZ581362A | New Zealand | A | |
| RU2470636C2 | Russian Federation | C2 | |
| US8343995B2 | United States of America | B2 | |
| US2013129700A1 | United States of America | A1 | |
| AU2008245550B2 | Australia | B2 | |
| AU2014200085A1 | Australia | A1 | |
| US8853236B2 | United States of America | B2 | |
| US2015025243A1 | United States of America | A1 | |
| JP5681485B2 | Japan | B2 | |
| CN101686681B | China | B | |
| KR20150041173A | Republic of Korea | A | |
| JP2015091857A | Japan | A | |
| CN104800210A | China | A | |
| AU2014200085B2 | Australia | B2 | |
| US9125945B2 | United States of America | B2 | |
| AU2015255164A1 | Australia | A1 | |
| US2016058786A1 | United States of America | A1 | |
| KR20160033792A | Republic of Korea | A | |
| IL201776A | Israel | A | |
| HK1212909A | Hong Kong, China | A | |
| HK1212909A1 | Hong Kong, China | A1 | |
| CA2685331C | Canada | C | |
| JP6076382B2 | Japan | B2 | |
| JP2017061533A | Japan | A | |
| US9623045B2 | United States of America | B2 | |
| AU2015255164B2 | Australia | B2 | |
| US2017173178A1 | United States of America | A1 | |
| KR101753131B1 | Republic of Korea | B1 | |
| JP6228286B2 | Japan | B2 | |
| JP2018021071A | Japan | A | |
| CA2921601C | Canada | C | |
| US10034947B2 | United States of America | B2 | |
| US2018326090A1 | United States of America | A1 | |
| BRPI0809838A2 | Brazil | A2 | |
| JP6496381B2 | Japan | B2 | |
| CN104800210B | China | B | |
| US10512697B2 | United States of America | B2 | |
| EP2152078B1 | European Patent Office (EPO) | B1 | |
| EP3766493A1 | European Patent Office (EPO) | A1 | |
| DK2152078T3 | Denmark | T3 | |
| EP2152078B8 | European Patent Office (EPO) | B8 | |
| HUE053158T2 | Hungary | T2 | |
| SI2152078T1 | Slovenia | T1 | |
| ES2855700T3This record | Spain | T3 | |
| BRPI0809838B1 | Brazil | B1 | |
| EP3766493B1 | European Patent Office (EPO) | B1 |
Numbers
- Publication
- 2855700
- Publication, DOCDB
- 2855700
- Publication, EPODOC
- ES2855700T
- Application
- 8769199
- Application, DOCDB
- 08769199
- Application, EPODOC
- ES20080769199T
Titles2
- Spanish
- Formulaciones que contienen clopidogrel y sulfoalquil éter-ciclodextrina y métodos de uso
- English
- Formulations containing clopidogrel and sulfoalkyl ether-cyclodextrin and methods of use
Classification
- CPC, 18
- A61K47/40
- A61K47/6951
- A61K9/0019
- A61K9/08
- A61K9/19
- A61K31/4365
- A61K31/44
- A61K31/724
- A61K31/727
- A61K45/06
- B82Y5/00
- A61K31/737
- A61P7/02
- A61P9/00
- A61P9/06
- A61P9/10
- A61K31/715
- A61K2300/00
- IPC, 14
- A61K47 40
- A61K31 4365
- A61K31 44
- A61K31 724
- A61K31 727
- A61K45 06
- A01N43 42
- A61K9 00
- A61K9 08
- A61K9 19
- B82Y5 00
- A61K31 737
- A61K47 69
- A61P7 02